{
    "code": "60001024",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001024",
    "time": "2021-06-18 03:19:53",
    "許可證字號": "衛部菌疫輸字第001024號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "110\/10\/09",
    "發證日期": "105\/10\/09",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000102401",
    "中文品名": "欣膝亞 200毫克\/毫升注射液",
    "英文品名": "Cimzia 200 mg\/ml solution for injection",
    "適應症": "1.類風濕性關節炎:用於治療對至少一種疾病調節抗風溼藥物(例如methotrexate)無適當療效之成人中至重度活動性類風濕性關節炎。和methotrexate併用時，Cimzia被證實可減緩關節傷害的惡化速度(以X光檢測)。 \r\n2.僵直性脊椎炎(AS):用於治療曾對非類固醇抗發炎藥物(NSAID)反應不佳或耐受性不良的重度活動性僵直性脊椎炎成人患者。 \r\n3.乾癬性關節炎:用於治療曾對DMARD療法反應不佳的活動性乾癬性關節炎成人患者。 \r\n4.乾癬:用於接受全身性治療或光療法的中度至重度斑塊性乾癬成人患者。 \r\n5.無放射影像確認之中軸性脊椎關節炎(Non-radiographic axial spondyloarthritis，簡稱nr-axSpA): 用於治療嚴重活動性無放射影像確認之中軸性脊椎關節炎且符合下列所有條件的成人患者:\r\n(1)對非類固醇抗發炎藥物(NSAID)治療反應不佳或無法耐受。 \r\n(2)其C反應蛋白(C-reactive protein，簡稱CRP)濃度升高。 \r\n(3)核磁共振造影(MRI)檢查證據顯示有發炎的客觀跡象。 \r\n(4)HLA-B27陽性。\r\n6.克隆氏症：用於對傳統治療無效之成人中度至重度克隆氏症(CD)，可減輕症狀與徵兆及維持臨床反應。",
    "劑型": "279注射液",
    "包裝": "1毫升玻璃注射針筒裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "110\/10\/09",
    "主成分略述": "Certolizumab pegol",
    "限制項目": "02輸　入 1D須執行風險管理計畫 51免除銜接性臨床試驗",
    "申請商名稱": "620101S739  台灣優時比貿易有限公司",
    "申請商地址": "台北市松山區敦化北路88號12樓之2",
    "主製造廠": [
        {
            "製造廠名稱": "FDE0292000  VETTER PHARMA-FERTIGUNG GMBH &amp; CO. KG",
            "製造廠廠址": "EISENBAHNSTRASSE 2-4, 88085 LANGENARGEN GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": "製劑、品管、一級包裝"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FAT0007000  Sandoz GmbH",
            "製造廠廠址": "BIOCHEMIESTRASSE 10, 6250 KUNDL AUSTRIA",
            "製造廠公司地址": "",
            "製造廠國別": "AUSTRIA",
            "製程": "主成分(drug substance)製造廠"
        },
        {
            "製造廠名稱": "FBE0061000  UCB PHARMA S.A.",
            "製造廠廠址": "ALLEE DE LE RECHERCHE, 60-1070 BRUSSELS, BELGIUM",
            "製造廠公司地址": "",
            "製造廠國別": "BELGIUM",
            "製程": "許可證持有者"
        },
        {
            "製造廠名稱": "FBE0064000  UCB PHARMA SA",
            "製造廠廠址": "CHEMIN DU FORIEST, B-1420 BRAINE-L&#39;ALLEUD, BELGIUM",
            "製造廠公司地址": "",
            "製造廠國別": "BELGIUM",
            "製程": "二級包裝、批次放行"
        },
        {
            "製造廠名稱": "FCH0292100  LONZA AG",
            "製造廠廠址": "LONZASTRASSE, CH-3930 VISP, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "主成分(drug substance)製造廠"
        },
        {
            "製造廠名稱": "Z102100001  UCB FARCHIM S.A.",
            "製造廠廠址": "Z.I. DE PLANCHY, CHEMIN DE CROX-BLANCE 10,CH-1630 BULLE SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "主成分(drug substance)製造廠"
        }
    ],
    "CCC號列": "30021500005 免疫產品，具有劑量或零售包裝式樣者Immunological products, put up in measured doses or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200094100",
            "成分名稱": "Certolizumab pegol",
            "含量描述": "",
            "含量": "200.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Cimzia Pro_patient in Chinese CD final submission20200930-109-10-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001024&Seq=008&Type=9"
        },
        {
            "title": "LBL_CIM_TW_MU1_領證20161130-105-12-01.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001024&Seq=002&Type=8"
        }
    ]
}